exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275258 RNA Name: hsa-miR-1270 RNA Type: miRNA Chromosome: chr19 Starnd: - Coordinate: Start Site(bp): 20399320 End Site(bp): 20399342 External Links: hsa-miR-1270

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MIEF1 chr22 39499432 39518132 + WIPF2 chr17 40219304 40284136 + GBA2 chr9 35736866 35749228 - HIF1AN chr10 100529072 100559998 + TCF12 chr15 56918623 57299281 + CDC42EP2 chr11 65314866 65322417 + LITAF chr16 11547722 11636381 - GRHL2 chr8 101492439 101669726 + PRLR chr5 35048756 35230487 - PATL1 chr11 59636716 59669037 - CACNG4 chr17 66964707 67033398 + ZNF652 chr17 49289206 49362473 - CDC37 chr19 10391133 10420121 - AGFG1 chr2 227472152 227561214 + SMG7 chr1 183472216 183598246 + TRIP6 chr7 100867387 100873454 + FN1 chr2 215360440 215436073 - DCBLD2 chr3 98795941 98901695 - BEND3 chr6 107065182 107115269 - NACC1 chr19 13116862 13141147 + TPM4 chr19 16067021 16103002 + TLNRD1 chr15 81000923 81005788 + SRGAP2 chr1 206203345 206464443 + PITPNA chr17 1517718 1562792 - FAM78A chr9 131258076 131276510 - ATP6V1B2 chr8 20197381 20226819 + VGF chr7 101162509 101165569 - PLAGL2 chr20 32192504 32207743 - PCDH10 chr4 133149294 133208606 + B4GALT5 chr20 49632945 49713878 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001247 chr22 46125304 46136418 + hsa_circ_0001159 chr20 40161688 40179999 - hsa_circ_0000471 chr13 33091993 33101669 - hsa_circ_0001666 chr6 170626457 170639638 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC239868.1 chr1 149861271 149862504 + AC245033.4 chr15 82533175 82540008 - AP000233.2 chr21 25095022 25103670 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - NR2F2-AS1 chr15 96110040 96327361 - OIP5-AS1 chr15 41283990 41309737 + SNHG12 chr1 28578538 28583132 - SNHG8 chr4 118278709 118285316 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.